University of California

Targegen, Inc.

Sidney Kimmel Cancer Center

San Diego Regional Cancer Center

Ivor Royston

Fred Harrison Gage

Robert E Sobol

John Hood

Wolfgang J Wrasidlo

Glenn Noronha

Theodore Friedmann

Elena Dneprovskaia

Harold H Handley

Habib Fakhrai

Ute Splittgerber

Xianchang Gong

J Edwin Seegmiller

Ningning Zhao

John Doukas

Theodore Friedman

Linda F Thompson

Gayle Yamamoto

John Majda

John D Hood

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

Vasculostatic agents and methods of use thereof

A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.

Lymphokine gene therapy of cancer

Cancer immunotherapy with carrier cells

Methods and compositions are provided for producing monoclonal antibodies capable of distinguishing between antigenic aggregates, which are differentiated by one or a small number of antigenic determinants. The method involves immunization of a mammal to produce spleen cells which are fused with a cell line which is stable in vitro. The hybridized cells are then dispensed into culture wells at a density level which encourages the production of one colony per well. Autologous antigenic aggregates are employed for screening to distinguish the antibodies which discriminate between the antigenic aggregates. Particularly, mice are hyperimmunized with a homogeneous population of T-cells, the immunized mice killed and the spleens removed. The spleen cells are fused with mouse myeloma cells and the resulting hybrids plated at a relatively low density in culture wells. Plates containing fewer than 30% hybrid positive wells are found to have primarily one colony per well. The cell supernatants are screened against autologous T- and B-cells and hybrid antibodies which do not bind to the B-cells are specific for T-cells.

Monoclonal antibody methods and compositions specific for single

Novel human lymphoblastoid cells and hybridomas derived therefrom are provided. The cells are a HGPRT negative human B-cell line. The cells are readily fusible with lymphoid cells to produce hybridomas which secrete human monoclonal antibodies.

Immunoglobulin-secreting human hybridomas from a cultured human

Growing community of inventors

La Jolla, CA, United States of America

Ivor Royston